Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company"), with the point-of-care system LAMPlify®, announces the expansion of its equine testing panel to include the detection of Equine Herpesvirus type 2 (EHV-2). This enhancement broadens the Company’s product portfolio and addresses an unmet need in equine health. The addition of EHV-2 not only increases the utility of LAMPlify but also opens up significant new opportunities in the global equine diagnostics market.
On 18 September 2025, Diagonal Bio announced that Stall Courant had placed an order for LAMPLify, following a successful pilot study. In connection with the pilot study, and in close collaboration with Stall Courant, Diagonal Bio has developed and validated a new test for EHV-2. This virus is common and linked to respiratory symptoms and skin disease in horses. Early and reliable detection is important for veterinarians and trainers to manage health risks, improve treatment decisions, and protect both individual horses and larger stables from potential outbreaks.
“By expanding our diagnostic test panel to include Equine Herpesvirus type 2, we are strengthening our offering in equine diagnostics. The demand for reliable and rapid testing continues to grow, and this addition allows us to address an even broader segment of the market. It is an important step in building a comprehensive portfolio for equine diseases while creating added value for our customers.” - Karin Wehlin, CEO of Diagonal Bio AB (publ)
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.